NCT01838967 is a Phase 1 clinical trial of C - V - C+V in Healthy, sponsored by IlDong Pharmaceutical Co Ltd.

Who is sponsoring NCT01838967?

NCT01838967 is sponsored by IlDong Pharmaceutical Co Ltd.

What drugs are being tested in NCT01838967?

Interventions in NCT01838967: C - V - C+V, C - C+V - V, V - C - C+V, V - C+V - C, C+V - C - V, C+V - V - C.

Is NCT01838967 still recruiting?

NCT01838967 is currently completed. Last updated 11 October 2013.

Last reviewed 2013-10-11 · How we verify

NCT01838967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Open-label, Single Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Cilnidipine 10 mg and Valsartan 160 mg After Oral Administration in Healthy Male Volunteers

Completed Phase 1 Last updated 11 October 2013

What this trial tests

Phase 1 trial testing C - V - C+V in Healthy in 54 participants. Completed in 1 October 2013.

Timeline

1 April 2013

Primary endpoint
1 June 2013

1 October 2013

Quick facts

Lead sponsor	IlDong Pharmaceutical Co Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 April 2013
Primary completion	1 June 2013
Estimated completion	1 October 2013
Sites	1 location across South Korea

Drugs / interventions tested

C - V - C+V — full drug profile →
C - C+V - V — full drug profile →
V - C - C+V — full drug profile →
V - C+V - C — full drug profile →
C+V - C - V
C+V - V - C — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

IlDong Pharmaceutical Co Ltd — full company profile →

Who can join

Adults 20 to 40, male only, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cmax of Cilnidipine 10 mg
Time frame: 1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose
Cmax of Valsartan 160 mg
Time frame: 1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose
AUClast of Cilnidipine 10 mg
Time frame: 1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose
AUClast of Valsartan 160 mg
Time frame: 1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose

Sponsor's own description

The investigators investigate the potential pharmacokinetic drug-drug interaction between Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10 mg alone, Valsartan 160 mg , and both together in a 3 period repeatedly.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
Lee J, Lee H, Jang K, Lim KS, et al · · 2014 · cited 9× · PMID 25336921 · DOI 10.2147/dddt.s68574

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other IlDong Pharmaceutical Co Ltd trials

Trials by the same sponsor.

NCT06635226 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects · Phase 1 · recruiting
NCT06063291 — Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects · Phase 1 · completed
NCT05663879 — Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers · Phase 1 · unknown
NCT05604287 — Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects · Phase 1 · terminated
NCT05259020 — To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01838967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IlDong Pharmaceutical Co Ltd
Last refreshed: 11 October 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01838967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing